SORT BY PROGRAM

Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1Q119X mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales
Publication Date
November 24, 2020
November 24, 2020

Activity of beta-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria
Publication Date
October 9, 2020
October 9, 2020

Metallo-Beta-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline
Publication Date
September 21, 2020
September 21, 2020

In vivo pharmacodynamics of new-generation beta-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-beta-lactamase-producing Gram-negative bacteria
Publication Date
August 30, 2020
August 30, 2020

In vitro activity of the novel beta-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China
Publication Date
July 15, 2020
July 15, 2020

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-Beta-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
Publication Date
December 23, 2019
December 23, 2019

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-Beta-Lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections
Publication Date
November 25, 2019
November 25, 2019

Interplay between beta-lactamases and new beta-lactamase inhibitors
Publication Date
March 5, 2019
March 5, 2019